演讲嘉宾--储以微

储以微
储以微
yiweichu@fudan.edu.cn
http://www.immunology.fudan.edu.cn/dawn/showResume.act?resume.id=2
复旦大学基础医学院,教授 复旦大学基础医学院免疫学系,主任 复旦大学生物治疗研究中心,主任
研究学习经历:

储以微,免疫学博士。中国免疫学会常务理事,中国免疫学会肿瘤生物治疗专业委员会常务理事。上海市免疫学会副理事长,上海市免疫学会感染与免疫专业主任委员。复旦大学生物治疗研究中心主任,基础医学院免疫学系主任。曾在美国华盛顿大学做访问学者,美国EACRI研究中心做访问教授,主要从事肿瘤免疫及免疫生物治疗,炎癌转化的免疫学机制研究等。在肿瘤患者放化疗后体内免疫系统重建及机制研究、TLRs抗肿瘤免疫效应及机制研究等方面取得了系列结果。发现Toll样受体激动剂作为一种免疫增强剂,通过直接或间接的方式在肺癌、黑色素瘤、白血病及脑胶质瘤中,诱导机体产生增强的抗肿瘤免疫应答,从而有效抑制肿瘤生长。建立了体外快速树突状细胞制备技术(Fast DC),获国家授权发明专利,并已完成《干细胞样抗原致敏树突状细胞疫苗治疗自体胶质母细胞瘤》前瞻性II期临床研究。构建了新型的特异性针对人表皮生长因子受体2(HER2)分子的第四代CAR结构,该新型的第四代HER2-CAR具有更丰富的作用方式、扩大了作用范围、增加了作用效果,已经获得针对表达HER2的消化道肿瘤I期临床试验批文,为实体肿瘤治疗开拓新途径。发表论文100余篇,含Cell Research, Hepatology, Cancer Research, Clinical Cancer Research, Mucosal Immunology, Journal of Immunology,Clinical Immunology, Cancer Immuno Immunotherapy 等杂志。担任《中国免疫学杂志》、《中国肿瘤生物治疗杂志》、《国际免疫学杂志》、《现代免疫学》等杂志编委,负责博士生《现代免疫学》、全英语课程《Medical Immunology》的授课及课程建设,其中《Medical Immunology》入选教育部首批来华留学英语授课品牌课程。主编教育部规划教材《免疫学与病原生物学》,参编《Tumor Immunology Cancer Vaccines》,《Cancer Immunotherapy》和《实用内科学》等专著。

代表性论文:
  1. Feifei Luo, Jiawen Qian, Jiao Yang, Yuting Deng, Xiujuan Zheng, Jie Liu*, Yiwei Chu* . aHER2/CD3 Bifunctional RNA Engineered CART-like Human T Cells Specifically Eliminate HER2+ Gastric Cancer. Cell Research 26:850-853(2016)
  2. Liu X, Jiang X, Liu R, Wang L, Qian T, Zheng Y, Deng Y, Huang E, Xu F, Chu Y*.B cells expressing CD11b effectively inhibit CD4+ T cell responses and ameliorate experimental autoimmune hepatitis in mice. Hepatology 62 :1563-1575(2015)
  3. L Wang, A Ray, X Jiang, J-y Wang, S Basu, X Liu, T Qian, R He, BN Dittel* and Y Chu*.T regulatory cells and B cells cooperate to form a regulatory loop that maintains gut homeostasis and suppresses dextran sulfate sodium-induced colitis .Mucosal Immunology 8:1297-1312(2015)
  4. Wei Lin, Zhichao Fan, Yuanzhen Suo, Yuting Deng, Min Zhang, Jiyang Wang, Xunbin Wei* and Yiwei Chu *. The bullseye synapse formed between CD4+ T-cell and staphylococcal enterotoxin B-pulsed dendritic cell is a suppressive synapse in T-cell response. Immunology and Cell Biology 93:99-110(2015)
  5. Ronghua Liu, Jie Gu, Pei Jiang, Yijie Zheng, Xiaoming Liu, Xuechao Jiang , Enyu Huang, Shudao Xiong,Fengkai Xu, Guangwei Liu, Di Ge*, Yiwei Chu*. DNMT1-microRNA126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9-EGFR-AKT signaling. Clinical Cancer Research 21:854-863(2015).
  6. Shudao Xiong, Yijie Zheng, Pei Jiang, Ronghua Liu, Xiaoming Liu, Jing Qian, Jie Gu, Lijun Chang, Di Ge, Yiwei Chu*. PA28gamma emerges as a novel functional target of tumor suppressor microRNA-7 in Non-Small Cell Lung Cancer. British Journal of Cancer 110: 353-362(2014)
  7. Zhang M, Luo F, Zhang Y, Wang L, Lin W, Yang M, Hu D, Wu X, Chu Y*. Pseudomonas aeruginosa Mannose-Sensitive Hemagglutinin Promotes T-Cell Response via Toll-Like Receptor 4-Mediated Dendritic Cells to Slow Tumor Progression in Mice. Journal of Pharmacology and Experimental Therapeutics 349: 279-287(2014)
  8. Yufei Zhang, Feifei Luo, Anning Li, Jiawen Qian, Zhenwei Yao, Xiaoyuan Feng, Yiwei Chu*. Systemic Injection of TLR1/2 Agonist Improves Adoptive Antigen-specific T Cell Therapy in Glioma-bearing Mice. Clinical Immunology 154 :26-36(2014)
  9. Qing Lu, Ji-Yang Wang, Luman Wang, Xuechao Jiang, Yiwei Chu*. Self DNA from lymphocytes 1 that have undergone activation-induced cell death enhances murine B cell proliferation and antibody production. PLoS One 9, e109095(2014)
  10. Yijie Zheng, Shudao Xiong, Pei Jiang, Ronghua Liu, Xiaoming Liu, Jing Qian, Xiujuan Zheng, Yiwei Chu*. Glucocorticoids inhibit lipopolysaccharide–mediated I inflammatory response by downregulation of microRNA-155: A novel anti- inflammation mechanism. Free radical biology and medicine 52: 1307-1317(2012)
  11. Yi Zhang, Feifei Luo, Yuchan Cai, Nan Liu, Luman Wang, Damo Xu and Chu Yiwei*. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. Journal of Immunology 186: 1963-1969. (Faculty of 1000) (2011)
会议报告摘要:
Bifunctional HER2/CD3 RNA-engineered CART-like Human T Cells Specifically Eliminate HER2+ Gastric Cancer (4月23日,14:20- 14:45 pm)

Genetically engineered T cells therapy is a promising strategy in cancer immunotherapy. One successful strategy is chimeric antigen receptor (CAR)-T cells therapy, but CARs-restricted on cell surface and side effects of retrovirus are partial limitations for CAR-T therapy. An alternative strategy is bispecific T cell engager (BiTE), but the therapeutic potential of BiTEs is still limited by the short half-life of antibodies, the lack of endogenous effector T cells in patients with advanced cancer, and severe adverse effects. In this study, we developed a novel secretable human epidermal growth factor receptor 2 (HER2)-targeting BiTE, HER2/CD3. These HER2/CD3 RNA engineered human T cells persistently secreted HER2/CD3 fusion proteins, which were released to help engineered T cell to exhibit HER2-specific activity, or redirect bystander T cells to HER2+ cancer cells and even inhibit HER2+ cancer cells proliferation directly. Additionally, HER2+ tumor-bearing mice treated with the secretable HER2/CD3 RNA engineered T cells got a significant tumor growth inhibition and prolonged survival without observed adverse effect. Thus, the secretable HER2/CD3 T cells have the characteristics of high potency, long term and low toxicity, which might offer an attractive HER2-targeting immunotherapy for solid tumors.

网站首页 | 会议简介 | 演讲嘉宾 | 大会日程 | 会议注册 | 交通/住宿 | 联系我们 |

第四届肿瘤基础和转化医学前沿国际研讨会